📉 The Financial Deep Dive
Pratiksha Chemicals Limited's Q3 FY26 results paint a grim picture of operational contraction, with revenue from operations plummeting by a stark 90.45% year-on-year to ₹16.03 lakhs from ₹167.91 lakhs in Q3 FY25. Total income mirrored this decline, dropping 86.63% to ₹22.67 lakhs. While total expenses were drastically cut by 95.53% to ₹3.37 lakhs, this did not offset the revenue collapse.
Profitability metrics showed a severe downturn. Profit After Tax (PAT) from continuing operations fell 98.32% YoY to ₹9.27 lakhs, a steep decline from ₹552.63 lakhs in the prior year's quarter. Consequently, Earnings Per Share (EPS) for continuing operations collapsed from ₹5.97 to just ₹0.17.
The company did report a Profit Before Tax (PBT) of ₹9.68 lakhs, a turnaround from a loss of ₹562.59 lakhs in Q3 FY25. However, this was significantly influenced by "Extraordinary Items" amounting to ₹8.62 lakhs, an impairment provision related to the anticipated sale of a substantial portion of the company's assets. This sale has been approved by shareholders and is a key event shaping the company's near-term future.
🚩 Risks & Outlook
The Auditor's Qualified Opinion: A Major Red Flag
The statutory auditors, Chandabhoy & Jassoobhoy, issued a qualified opinion, a significant concern for investors. The primary reason cited is the company's non-compliance with accounting standards (Ind AS-1 and Ind AS-19) and Section 133 of the Companies Act, 2013, by accounting for gratuity and leave encashment on a cash basis. The exact financial impact of this deviation could not be ascertained. Furthermore, the comparative figures for Q3 FY25 were not reviewed by the auditor, relying solely on management compilation, which further erodes confidence in the presented data.
Strategic & Operational Concerns
The drastic drop in revenue points to a severe slowdown in core operations. The approved asset sale signals a potential restructuring or divestment of key business segments. Management has provided no specific guidance or outlook for future performance, leaving investors uncertain about the company's path forward. The lack of clarity on operational recovery and the auditor's severe reservations on accounting practices are critical points of risk. Investors should closely monitor any disclosures regarding the asset sale and the company's steps to rectify accounting non-compliance.
